AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 291 min read$BIVI

KIM JOANNE WENDY purchased $5K of BIVI

KIM JOANNE WENDY (Chief Financial Officer) purchased 2,500 shares of BIOVIE INC. (BIVI) at $2.18 on 2026-08-28.

Original reporting
SEC EDGAR · KIM JOANNE WENDY
Published Aug 29, 2026, 12:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 29, 2026, 1:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BIVI
Neutral
low confidence
Mentioned
$BIVI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BIVINeutralLow
01

Why it matters

The CFO's purchase is a routine insider trade with limited material impact.

02

Market read

Minor insider purchase; unlikely to affect broader market.

03

What to watch

Potential upcoming corporate actions not disclosed in the filing.

Relevance 4/10Novelty 3/10Timing: post‑market filing on 2026‑08‑28

Background

Form 4 disclosures are primary sources for insider transactions.

Company-level read

Ticker impact

$BIVINeutralLow confidence
Context

CFO Kim Joanne Wendy bought 2,500 shares of BIOVIE Inc. for $5,450 in a Form 4 filing.

Expected impact

Minimal price movement expected.

Evidence & confidence

Purchase size is modest ($5k) for a micro‑cap; unlikely to move the stock significantly.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider buying could be a subtle confidence signal despite small size.

Key entities

  • Company
    BIOVIE Inc.

    Biotech firm listed under ticker BIVI.

  • Insider
    Kim Joanne Wendy

    Chief Financial Officer of BIOVIE Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BIVI insider trading history →

Related articles

SEP 16
$BIVIMedAI 8/10

RedChip Companies, Inc.: Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 Results

BioVie (NASDAQ:BIVI) will host an investor webinar on September 23, 2026, to discuss Phase 2 results of its drug bezisterim for Long COVID. CEO Cuong Do will present findings showing potential across key symptoms and discuss implications for neurological disorders. The company believes positive results could support bezisterim's development for multiple CNS conditions.

finanznachrichten.de2 min
SEP 15
$BIVIMedAI 8/10

BioVie Phase 2 trial shows bezisterim eases fatigue, cognitive symptoms in severe Long COVID cases

BioVie Inc. reported Phase 2 trial results for bezisterim, showing statistically significant symptom improvements in severe Long COVID patients with high baseline disease burden. The 203-patient trial evaluated 22 clinical outcomes and biomarkers. Subgroup analyses showed significant improvements in fatigue, cognitive impairment, and other symptoms. The company plans further Phase 3 trials to confirm these results. According to the company, bezisterim may become the first therapy for neurologica

proactiveinvestors.com2 min
SEP 15
$BIVIMedAI 8/10

BioVie's Bezisterim Shows Phase 2 Signal In Long COVID; Stock Down

BioVie Inc. (BIVI) reported Phase 2 trial results for Bezisterim, showing significant improvements in Long COVID patients with high baseline fatigue and cognitive impairment. The drug demonstrated advantages over placebo on 21 of 22 endpoints and had a similar safety profile to placebo. BioVie plans to advance to Phase 3 trials. BIVI stock is down 8.23% in pre-market trading.

rttnews.com2 min
SEP 15
$BIVIMedAI 9/10

BioVie, Inc.: BioVie Announces Topline Results from Phase 2 ADDRESS-LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

BioVie Inc. (BIVI) reported positive Phase 2 trial results for bezisterim, showing statistically significant benefits in Long COVID patients with high baseline fatigue, cognitive impairment, and post-exertional malaise. The drug outperformed placebo on 21 of 22 endpoints in these subgroups, with a safety profile similar to placebo. The company plans to discuss the results in a conference call today.

finanznachrichten.de2 min
SEP 8
$BIVIMed

BioVie advances Parkinson’s Phase 3 development program with FDA engagement

BioVie Inc. (BIVI, BIVIW) announced plans to advance its Phase 3 trial for bezisterim in Parkinson’s disease, with an End-of-Phase 2 meeting requested with the FDA. The trial will focus on motor symptoms (MDS-UPDRS Part III) as the primary endpoint, with non-motor symptoms (MDS-UPDRS Part I) as a co-primary or secondary endpoint. Phase 2 results suggested greater benefits for patients with higher inflammation levels. The company expects to discuss the trial design with the FDA later this year an

proactiveinvestors.com2 min